|
ELOVL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.42340000184061E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.97740000221714E-08 |
| Normal-vs-Stage2 |
6.19939999335628E-09 |
| Normal-vs-Stage3 |
6.98559999845472E-08 |
| Normal-vs-Stage4 |
3.45359999487371E-08 |
| Stage1-vs-Stage2 |
3.371600E-02 |
| Stage1-vs-Stage3 |
8.526400E-01 |
| Stage1-vs-Stage4 |
4.012200E-01 |
| Stage2-vs-Stage3 |
8.273900E-02 |
| Stage2-vs-Stage4 |
2.807800E-01 |
| Stage3-vs-Stage4 |
5.410400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.6849000052448E-08 |
| Normal-vs-AfricanAmerican |
3.45160000025935E-07 |
| Normal-vs-Asian |
5.77980000526779E-08 |
| Caucasian-vs-AfricanAmerican |
8.184200E-01 |
| Caucasian-vs-Asian |
5.372200E-01 |
| AfricanAmerican-vs-Asian |
5.564000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.79069999623516E-08 |
| Normal-vs-Female |
4.01640000147196E-08 |
| Male-vs-Female |
5.785600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66029999970618E-07 |
| Normal-vs-Age(41-60Yrs) |
1.67070000056668E-08 |
| Normal-vs-Age(61-80Yrs) |
2.91720000378248E-08 |
| Normal-vs-Age(81-100Yrs) |
2.415400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.442290E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.127020E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.992770E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.962200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.523160E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.367900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.642400E-01 |
| Classical-VS-Follicular |
8.23910000002925E-07 |
| Classical-VS-Other |
3.304300E-02 |
| Classical-VS-Normal |
2.42870000000117E-07 |
| Tall-VS-Follicular |
3.643100E-03 |
| Tall-VS-Other |
2.383600E-02 |
| Tall-VS-Normal |
3.91429999968551E-07 |
| Follicular-VS-Other |
5.897400E-01 |
| Follicular-VS-Normal |
2.20810003614957E-09 |
| Other-VS-Normal |
2.14399999975967E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03999999723214E-08 |
| Normal-vs-N1 |
7.05839999781688E-08 |
| N0-vs-N1 |
3.056600E-01 |
|
|
